Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies

Leah Burns · Robert Kalesnik-Orszulak · Rick Spring · Fabienne Zeegers · Mark Rutstein · Mathias Hukkelhoven · Lisa Wruck · John O’Donnell

Received: February 17, 2021 / Accepted: July 1, 2022 / Published online: August 16, 2022 © The Author(s) 2022

ABSTRACT

Real-world evidence (RWE) is increasingly used to complement clinical trial data for regulatory decision-making and in certain cases utilized to establish the clinical effectiveness of a therapy. However, the use of RWE is not applicable for all regulatory submissions, and it can be challenging to identify appropriate use cases. An interactive tool was developed (“Decision Aid,” https://sn.pub/TpDjZx) to assist researchers, industry, and other stakeholders in identifying regulatory situations that can benefit from leveraging RWE by organizing precedent cases based on a given regulatory objective (new product approval, labeling expansion for new indication or additional clinical data, post-marketing requirement) and type of RWE study design (external control, observational study, pragmatic trial). Key success factors ensuring fit-for-purpose data and rigorous methods (e.g., clear endpoints, minimizing bias, data completeness) are also described. The tool allows the user to navigate through the precedent cases by selecting certain regulatory objectives and/or study designs. The Decision Aid supports regulatory activities in the RWE space and encourages further use of RWE in regulatory decision-making.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s12325-022-02257-4.
Decision Aid; External control; Observational study; Pragmatic trial; Real-world evidence; Regulatory decision-making

**Key Summary Points**

The aim of this paper is to describe an interactive Decision Aid designed to:

Serve as a tool for researchers, industry, and other stakeholders to identify areas of opportunity for real-world evidence (RWE) to support regulatory strategies and clinical development plans.

Illustrate key uses of RWE for regulatory purposes (by utilizing precedent cases where RWE was successfully used to support regulatory decisions), corresponding RWE study designs, and underlying key success factors.

Encourage further use of RWE and activity in this space to add to the growing evidence and establishment of RWE in regulatory submissions.

This manuscript and associated Decision Aid are intended to help researchers identify potential use cases in which RWE might be considered to inform regulatory decision-making.

**INTRODUCTION**

Real-world evidence (RWE) has traditionally played a relatively limited role in the regulatory process, for example, addressing unmet need and satisfying post-marketing safety monitoring requirements. In the current evolving healthcare landscape, however, there has been a shift towards utilizing RWE in a more central and fit-for-purpose role through identifying situations in which RWE can help establish the clinical effectiveness of a therapy to support regulatory decision-making rather than only to supplement insights from clinical trials [1].

In the US, the Framework for the Food and Drug Administration’s (FDA’s) RWE Program was released in December 2018 and outlines several important RWE-related efforts the Agency is undertaking to evaluate the potential of RWE to support changes to labeling, such as adding or modifying an indication, a change in dose, dose regimen, or route of administration; adding a new population; or adding comparative effectiveness or safety information [2]. In Europe, the European Medicines Agency’s (EMA’s) Regulatory Science Strategy 2025 initiative includes the promotion of high-quality RWE in decision-making to generate complementary evidence across the product lifecycle as one of its five strategic goals [2]. RWE initiatives are being conducted by other global health authorities around the world as well, including in Canada [3], China [4], and Japan [5], to encourage and optimize the use of RWE for regulatory decisions, while focusing on the reliability and quality of evidence. Given the increasing interest in leveraging RWE for regulatory decision-making, there have been many recent publications on insights and recommendations on ways to ensure fit-for-purpose RWE [6–9]. In addition, the currently ongoing COVID-19 pandemic has further reinforced and accelerated Health Authorities’ interest in the potential utility of RWE [10–12].

Despite the growing interest in leveraging RWE by industry and evaluation of RWE by Health Authorities for regulatory decision-making, it is important to note that RWE is not applicable to all situations and should not be considered a replacement for clinical trials [13]. Regulatory
acceptance of RWE to support data from clinical trials is subject to the respective Health Authority's approaches and practices. The authors of this manuscript developed an interactive tool (“Decision Aid”) to assist in more easily identifying circumstances in which the use of RWE informed regulatory decision-making (Figure 1; https://sn.pub/TpDjZx). To date, RWE has been used in certain situations to support new product approvals, label expansions for new indications or additional clinical data, and fulfillment of post-marketing requirements. In such cases, various real-world (RW) or RW-clinical hybrid designs have been utilized, including external controls (external benchmarks or external comparators), observational studies, and pragmatic clinical trials. There are various factors, such as the rarity of the disease, magnitude of treatment effect, availability of quality RWD, and others, that can help inform the appropriateness of a RWE approach for regulatory decision-making. These factors can be better understood by reviewing precedent cases in this space.

The aim of this paper is to describe an interactive Decision Aid designed to:

- Serve as a tool for researchers, industry, and other stakeholders to identify areas of opportunity for RWE to support regulatory strategies and clinical development plans.
- Illustrate key uses of RWE for regulatory purposes (by utilizing precedent cases where RWE was successfully used to support regulatory decisions), corresponding RWE study designs, and underlying key success factors.
- Encourage further use of RWE and activity in this space to add to the growing evidence and establishment of RWE in regulatory submissions.

This article and associated Decision Aid are intended to help researchers identify potential use cases in which RWE might be considered to inform regulatory decision-making.

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not contain any new studies with human participants or animals.

METHODS

Several case examples in which RWE was leveraged to support successful FDA and EMA regulatory submissions were selected and described based on a systematic review of regulatory labels, published literature, and regulatory assessment reports. Each case study was matched with the regulatory objective obtained (new product approval, labeling expansion for new indication or additional clinical data, post-marketing requirement) as well as the type of RWE study design used (external control, observational study, pragmatic trial). Based on this matching, the Decision Aid was organized accordingly by regulatory objective and RWE study design type.

Case studies were assessed for key success factors that have been described in the context of ensuring fit-for-purpose data and rigorous methods, which contributed to a positive regulatory opinion. The assessment was based on a checklist to ensure regulatory-grade data quality (completeness, transparency, generalizability, timeliness, scalability) [14], supplemented by additional considerations around clear end-point definitions and strategies for minimizing bias for a careful assessment of data quality, reliability, and relevance [2, 15, 16]. Providing clear definitions of primary and secondary endpoints is important to avoid variable documentation of key events potentially influenced by subjectivity. RWD often encompasses a broader spectrum of patients which leads to better generalizability than clinical trials, but potential biases need to be considered and mitigated to allow for adequate interpretation of results. Pre-defined data abstraction, harmonization, and quality monitoring are key markers of quality, integrity, and completeness. Being transparent with Health Authorities around the study design deployed, whether in protocols, analysis plans, or reporting of study results, is another key success factor to allow Health Authorities to rigorously assess the RWE submitted. Leveraging recent and timely RWD ensures the data provide relevant insights around clinical decision-making and adequately reflects the dynamic nature of routine medical

△ Adis
practice and treatment use. For data that were
intended for scaling, data curation processes,
applicability to multiple contexts, and variable
definitions were also assessed.

The Decision Aid includes case studies on
pharmaceutical products from multiple manu-
facturers and includes case studies that were
available at the time this manuscript was draf-
ted. The authors intend to submit annual
updates as the regulatory landscape, frame-
works, and case studies change.

REGULATORY USE DECISION AID

The Decision Aid can be accessed at https://sn.
pub/TpDjZx.

Users can navigate through the Decision Aid
by using sequential multi-step navigation as the
tool matches the regulatory objective being
evaluated with the corresponding key success
factors, the most applicable RWE study types,
and real-life precedent cases for reference.

• When opening the tool, the general RWE
success factors are described, key terms are
defined, and an overview of the case studies
is provided.

• When clicking on a particular regulatory
objective (new product approval, label
expansion, and post-marketing require-
ment), the most applicable corresponding
RWE study types are displayed, including
external control, observational study, or
pragmatic clinical trial.

• After selecting a specific RWE study type, the
tool will display corresponding real-life
precedent case studies for that specific com-
bination of regulatory objective and study
type, covering multiple therapeutic areas.
  o Individual case examples include key
    information, such as narrative and rele-
    vant success factors.
  o Each case study also includes hyperlinks
to regulatory assessment reports to facil-
    itate further reading.

• The user can navigate forward and backward
throughout the tool to access all
information.

The list of case studies included in the
Decision Aid is not exhaustive, as new case
studies potentially became available after the
tool was developed.

DISCUSSION

The Decision Aid will help guide pharmaceuti-
cal companies and clinical researchers in
assessing general appropriateness of a potential
RWE approach for use in clinical development
within a regulatory context. The Decision Aid
does not aim to replace Health Authority guid-
ance or the critical importance of engaging
Health Authorities on RWE proposals early on
to gather their feedback on the proposed
approach, but the tool can help identify
potential opportunities for leveraging RWE to
inform certain regulatory objectives. It is this
identification step that the Decision Aid aims to
focus on. Further comprehensive assessment
based on the particulars of a situation may be
necessary to confirm whether a real-world evi-
dence-based approach for a particular scenario
is appropriate.

CONCLUSION

RWE has been increasingly used in later stages
of drug development. Importantly, the intent of
RWE is not to replace clinical trials but to apply
RWE where appropriate to support drug devel-
opment and ultimately regulatory submissions.
Through identifying and illustrating key aspects
of situations where RWE has been utilized for
regulatory decision-making, the Decision Aid
helps pharmaceutical companies and clinical
researchers understand the type of potential
evidence necessary for regulatory submissions,
adds to the knowledge of available RWE, and
encourages further regulatory activity using
RWE to pave the way for broader acceptance by
clinical researchers, pharmaceutical companies,
and Health Authorities. To maximize the
chances for success, any research proposal that
intends to be used for regulatory decision-
making should be discussed with the relevant
Health Authority before the research is started.
ACKNOWLEDGEMENTS

**Funding.** Funding for the study and the journal’s Rapid Service and Open Access fees was provided by Bristol-Myers Squibb (BMS).

**Medical Writing and Editorial Assistance.** We thank Eva Oakkar, IQVIA, for medical writing assistance and interactive Decision Aid development. This assistance was funded by BMS.

**Authorship.** All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

**Author Contributions.** Employees of Bristol-Myers Squibb Company: Leah Burns, Conception, Data Acquisition, Data Analysis, Data Interpretation. Robert Kalesnik-Orszulak, Conception, Data Acquisition, Data Interpretation. Rick Spring, Conception, Data Acquisition, Data Interpretation. Fabienne Zeegers, Conception, Data Interpretation. Mark Rutstein, Conception, Data Interpretation. Mathias Hukkelhoven, Data Interpretation. John O’Donnell, Conception, Data Interpretation. Funded by Bristol-Myers Squibb Company: Lisa Wruck, Data Interpretation, has received research grants from Bristol-Myers Squibb Company.

**Disclosures.** Leah Burns, Robert Kalesnik-Orszulak, Rick Spring, Fabienne Zeegers, Mark Rutstein, Mathias Hukkelhoven and John O’Donnell are employees of Bristol-Myers Squibb Company. Lisa Wruck did not receive funding for this project, but has received research grants from BMS previously.

**Compliance with Ethics Guidelines.** This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

**Data Availability.** No datasets were generated or analysed during the current study.

**Open Access.** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

APPENDIX 1: GLOSSARY

**External Control**

External control data is any data generated from patients external to the parameters of the parent trial and used to provide context to a single-arm study where it would be impractical or ethical to design the study with a placebo or active comparator arm [17].

**External Benchmark**

A subtype of external control, in which real-world populations are used to provide context on outcomes. In this case, no direct comparison is made with the trial data, the data is aggregated.
External Comparator

A subtype of external control, in which patient-level RWD are used for a comparison versus the clinical data.

Observational Study

A type of study in which individuals are observed or certain outcomes are measured. No attempt is made to affect the outcome (for example, no treatment is given) [18].

Pragmatic Trial

Pragmatic trial is designed to test interventions in the full spectrum of everyday clinical settings in order to maximize applicability and generalizability [19].

Bias

In a scientific research study or clinical trial, a flaw in the study design or the method of collecting or interpreting information. Biases can lead to incorrect conclusions about what the study or clinical trial showed [18].

Real World Evidence (RWE)

RWE is the clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of real-world data (RWD) [1].

Real World Data (RWD)

RWD are data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources [1].

Effectiveness (in Contrast to Efficacy)

While RCTs provide evidence of therapeutic efficacy in a controlled setting, real-world studies produce evidence of therapeutic effectiveness in real-world practice settings [20].

RW-Clinical Hybrid Design

RW-clinical hybrid design is an integration of a traditional clinical trial with pragmatic design aspects to collect RWD on patients (21).

REFERENCES

1. Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther. 2019;106(1):36–9.
2. US Food and Drug Administration. Framework for FDA’s real-world evidence program. 2018. https://www.fda.gov/media/120060/download. Accessed Jul 2020.
3. European Medicines Agency. Glanville, D. Regulatory Science to 2025. 2018. https://www.ema.europa.eu/en/about-us/how-we-work/regulatory-science-strategy. Accessed Jul 2020.
4. Government of Canada. Optimizing the use of real world evidence to inform regulatory decision-making. 2019. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/optimizing-real-world-evidence-regulatory-decisions.html. Accessed Jul 2020.
5. China Center for Drug Evaluation. Key considerations in using real-world evidence to support drug development. 2019. https://www.chcuk.co.uk/china-key-considerations-in-using-real-world-evidence-to-support-drug-development/. Accessed Jul 2020.
6. Pharmaceuticals and Medical Devices Agency (Japan). PMDA Updates. 2019. https://www.pmda.go.jp/files/000231353.pdf. Accessed Jul 2020.
7. Dreyer NA. Advancing a framework for regulatory use of real-world evidence: when real is reliable. Ther Innov Regul Sci. 2018;52(3):362–8.
8. Mack C, Christian J, Brinkley E, Warren EJ, Hall M, Dreyer N. When context is hard to come by: external comparators and how to use them. Ther Innov Regul Sci. 2019. https://doi.org/10.1177/2168479019878672.
9. Baumfeld Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA. Trial designs using real-world data: the changing landscape of the regulatory approval process. Pharmacoepidemiol Drug Saf. 2020;29(10):1201–12.
10. Beaulieu-Jones BK, Finlayson SG, Yuan W, Altman RB, Kohane IS, Prasad V, et al. Examining the use of real-world evidence in the regulatory process. Clin Pharmacol Ther. 2020;107(4):843–52.

11. US Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Collaborations Promote Rigorous Analyses Of Real-World Data To Inform Pandemic Response. 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-collaborations-promote-rigorous-analyses-real-world-data-inform. Accessed Sep 2020.

12. US Food and Drug Administration. Coronavirus (COVID-19) Update: FDA takes additional action to harness real-world data to inform COVID-19 response efforts. 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-additional-action-harness-real-world-data-inform-covid-19. Accessed Sep 2020.

13. Donnell JC, Kim-Le T, Dobrin R, Higashi M, Pereira A, Wagner S, Yang A, Hukkelhoven M. Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes. Future Oncol. 2020;17:333–47.

14. Miksad RA, Abernethy AP. Harnessing the power of real-world evidence (RWE): a checklist to ensure regulatory-grade data quality. Clin Pharmacol Ther. 2018;103(2):202–5.

15. Duke-Margolis Center for Health Policy. Determining real-world data’s fitness for use and the role of reliability. 2019. https://healthpolicy.duke.edu/publications/determining-real-world-datas-fitness-use-and-role-reliability. Accessed Jan 2021.

16. Kahn MG, Callahan TJ, Barnard J, Bauck AE, Brown J, Davidson BN, et al. A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data. EGEMS (Wash DC). 2016;4(1):1244.

17. Arone B. The argument for external comparator adoption. Pharmaceut Execut. 2019;36:6.

18. NIH. NCI Dictionary: Retrieved from observational study. 2020. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/observational-study. Accessed Jan 2021.

19. Patsopoulos NA. A pragmatic view on pragmatic trials. Dialogues Clin Neurosci. 2011;13(2):217–24.

20. Luce BR, Drummond M, Jönsson B, Neumann PJ, Schwartz JS, Siebert U, Sullivan SD. EBM, HTA, and CER: clearing the confusion. Milbank Q. 2010;88(2):256–76.

21. Zhu M, Sridhar S, Hollingsworth R, Chit A, Kimball T, Murrello K, Greenberg M, Gurunathan S, Chen J. Hybrid clinical trials to generate real-world evidence: design considerations from a sponsor’s perspective. Contemp Clin Trials. 2020;94: 105856.